Loading
IMBdx's personalised blood test for leftover cancer, from Seoul, which adds a set of common treatable mutations to the patient's own.
CancerDetect, formerly reported as AlphaLiquid Detect, is the residual disease test of IMBdx of Seoul. Its analytical validation (Heo et al., PLoS One 2025) combines personalised mutations with tumour-agnostic hotspot mutations and reports a limit of detection of 0.001 per cent with 99.9 per cent specificity. The full text measured that limit on a cell-line mixture of 385 germline single-nucleotide polymorphisms rather than on tumour mutations, and the hotspot regions had a separate limit of 0.1 per cent.
A bespoke capture panel of patient-specific mutations from tumour sequencing, combined with tumour-agnostic actionable hotspot targets, read with molecular barcodes.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CancerDetect" OR ABSTRACT:"CancerDetect" OR TITLE:"IMBdx CancerDetect" OR ABSTRACT:"IMBdx CancerDetect" OR TITLE:"AlphaLiquid Detect" OR ABSTRACT:"AlphaLiquid Detect") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CancerDetect, not a curated reading list.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/